Commerce Bank Decreases Stake in HCA Healthcare, Inc. (NYSE:HCA)

Commerce Bank reduced its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 13.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,830 shares of the company's stock after selling 1,567 shares during the period. Commerce Bank's holdings in HCA Healthcare were worth $3,397,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of HCA. GAMMA Investing LLC raised its stake in HCA Healthcare by 40,527.3% during the first quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company's stock worth $5,887,850,000 after purchasing an additional 1,699,713 shares during the period. Pacer Advisors Inc. raised its stake in HCA Healthcare by 6,237.9% during the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company's stock worth $466,815,000 after purchasing an additional 1,329,618 shares during the period. Barclays PLC raised its stake in HCA Healthcare by 85.7% during the fourth quarter. Barclays PLC now owns 1,061,891 shares of the company's stock worth $318,727,000 after purchasing an additional 489,916 shares during the period. Two Sigma Investments LP raised its stake in HCA Healthcare by 12,016.0% during the fourth quarter. Two Sigma Investments LP now owns 467,437 shares of the company's stock worth $140,301,000 after purchasing an additional 463,579 shares during the period. Finally, ANTIPODES PARTNERS Ltd raised its stake in shares of HCA Healthcare by 1,415.0% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 435,423 shares of the company's stock valued at $150,472,000 after acquiring an additional 406,682 shares during the period. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Trading Up 0.8%

NYSE HCA opened at $356.84 on Monday. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $417.14. The stock has a market capitalization of $85.84 billion, a PE ratio of 15.00, a price-to-earnings-growth ratio of 1.12 and a beta of 1.39. The firm has a 50 day moving average of $370.66 and a two-hundred day moving average of $347.68.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its earnings results on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The business had revenue of $18.61 billion during the quarter, compared to analysts' expectations of $18.49 billion. During the same quarter in the prior year, the business posted $5.50 EPS. The company's revenue for the quarter was up 6.4% on a year-over-year basis. As a group, research analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, September 16th. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. HCA Healthcare's dividend payout ratio is presently 12.11%.

Insider Activity

In related news, COO Jon M. Foster sold 15,698 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $369.32, for a total value of $5,797,585.36. Following the completion of the sale, the chief operating officer owned 12,646 shares in the company, valued at $4,670,420.72. This represents a 55.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on HCA shares. Guggenheim started coverage on shares of HCA Healthcare in a research note on Wednesday, April 9th. They issued a "neutral" rating on the stock. Morgan Stanley reduced their price target on shares of HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating on the stock in a research note on Monday, July 28th. Bank of America downgraded shares of HCA Healthcare from a "buy" rating to a "neutral" rating and set a $394.00 price target on the stock. in a research note on Wednesday, July 16th. Baird R W cut shares of HCA Healthcare from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 15th. Finally, Truist Financial lifted their price objective on shares of HCA Healthcare from $390.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, July 16th. Nine equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, HCA Healthcare currently has an average rating of "Moderate Buy" and a consensus price target of $396.46.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.